Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.56 |
| ▸ | LPL | P06858 | 6/20 | 0.56 |
| ▸ | F11 | P03951 | 3/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA9 | Q16790 | 4/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30858793 | 1.00 | LIPG (0.56) | LIPGLPLF11ROCK1F2 | |
| SCHEMBL13967586 | 0.87 | LIPG (0.57) | LIPGLPLF11ROCK1F2 | |
| SCHEMBL108008 | 0.87 | LIPG (0.57) | LIPGLPLF11ROCK1F2 | |
| SCHEMBL137029 | 0.83 | LIPG (0.53) | LIPGLPLF11ROCK1HIF1A | |
| SCHEMBL13336438 | 0.83 | LIPG (0.53) | LIPGLPLF11ROCK1HIF1A | |
| SCHEMBL5332795 | 0.82 | LIPG (0.52) | LIPGLPLF11ROCK1F2 | |
| SCHEMBL26492122 | 0.82 | LIPG (0.52) | LIPGLPLF11ROCK1F2 | |
| SCHEMBL514356 | 0.81 | F11 (0.60) | LIPGLPLF11F2PRSS1 | |
| SCHEMBL1238039 | 0.81 | LIPG (0.54) | LIPGLPLROCK1HIF1AP4HB | |
| SCHEMBL27195055 | 0.81 | LIPG (0.54) | LIPGLPLROCK1HIF1ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352550-A1 | SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE | UNIV MASARYKOVA (CZ) | 2025-11-20 | — | — | US | disclosed |
| EP-4602046-A1 | SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE | Masarykova Univerzita (CZ) | 2025-08-20 | — | — | EP | disclosed |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2025-06-24 | — | — | US | disclosed |
| US-20240287020-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2024-08-29 | — | — | US | disclosed |
| WO-2024102946-A2 | BORON-BASED ENOLASE LIGANDS AND METHODS OF USE FOR TREATMENT OF CANCER | LOMA LINDA UNIVERSITY (US) | 2024-05-16 | — | — | WO | disclosed |
| US-11970474-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) | 2024-04-30 | — | — | US | disclosed |
| CN-112074511-B | Substituted benzodiazoles and their use in therapy | 托马斯·黑勒戴药物研究基金会 | 2024-04-26 | — | — | CN | disclosed |
| WO-2024078649-A1 | SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE | MASARYKOVA UNIVERZITA (CZ) | 2024-04-18 | — | — | WO | disclosed |
| EP-4353727-A1 | SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE | Masarykova Univerzita (CZ) | 2024-04-17 | — | — | EP | disclosed |
| CN-117756834-A | Synthesis method of 2- (aminocarbonylmethyl) phenylboronic acid pinacol ester | 大连双硼医药化工有限公司 | 2024-03-26 | — | — | CN | disclosed |
| US-20090292014-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-11-26 | — | — | US | disclosed |
| US-20090292014-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-11-26 | — | — | US | disclosed |
| WO-2009074829-A1 | PEPTIDYL NITRILES AND USE THEREOF AS DIPEPTIDYL PEPTIDASE I INHIBITORS | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | WO | disclosed |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-01-22 | — | — | US | disclosed |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-01-22 | — | — | US | disclosed |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-01-22 | — | — | US | disclosed |
| US-7420066-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-7420066-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-7420066-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060194816-A1 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAER PHAMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292014-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | PCNA, MKI67, CDK4 | LIPG 3448/4885LPL 3456/4885F11 3519/4885 |
| US-20060194816-A1 | Benzofuran derivatives useful for treating hyper-proliferative disorders | MKI67, PCNA, CCNI | LIPG 3791/4885LPL 3922/4885F11 2376/4885 |
| US-20250352550-A1 | SUBSTITUTED FUROPYRIDINES FOR THERAPEUTIC USE | FLT3, ROS1, MAP4K2 | LIPG 3782/4885LPL 4726/4885F11 4605/4885 |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | PCNA, MKI67, CDK4 | LIPG 3448/4885LPL 3456/4885F11 3519/4885 |
| US-11970474-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP4X1, CYP11B2 | LIPG 4601/4885LPL 4498/4885F11 393/4885 |
| US-20240287020-A1 | SUBSTITUTED BENZODIAZOLES AND USE THEREOF IN THERAPY | XDH, CYP11B2, CYP4X1 | LIPG 4554/4885LPL 4520/4885F11 325/4885 |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP11B2, CYP4X1 | LIPG 4554/4885LPL 4520/4885F11 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.